Fig. 3From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancersInduction of T-cell proliferation. CD4 (upper panel) and CD8 (lower panel) T-cell proliferation analysis after six days of co-culture with CEACAM5-positive cell lines SK-CO-1, MKN-45, and H2122. BsAb, bispecific antibodyBack to article page